BioSpace News Archive

As federal lawmakers continue to wrangle over legislation to help curb the opioid crisis in the United States, the House of Representatives is showing some division over the costs that some pharmaceutical companies may have to pay for Medicare coverage.

San Francisco-based uBiome snagged $83 million in a Series C financing round and also tapped industry veteran Joe Jimenez, the former chief executive officer of Swiss pharma giant Novartis, to its board of directors.

Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the first time, forecasted the disease by race and ethnicity.

A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.

The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August.

Some cancer cells have a remarkable and frightening sense of self-preservation to avoid immunotherapy treatments. That is the finding from a new study conducted by researchers at the Fred Hutchinson Cancer Research Center in Seattle.

Here’s a look at who’s making moves in the biotech and pharma world this week.